Evidence map›Paper›PMID 41234154›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis.

Caihua Liang, Jennifer Judy, Erica L Chilson, Scott P Kelly, Qing Liu, Jason D Maynard, Heidi De Souza, Bradford D Gessner, Elizabeth Begier

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Caihua LiangVaccines RWE Epidemiology, Pfizer Inc., New York, NY, USA.
Jennifer JudyVaccines RWE Epidemiology, Pfizer Inc., New York, NY, USA.
Erica L ChilsonVaccines RWE Epidemiology, Pfizer Inc., New York, NY, USA.ORCID 0000-0002-4417-3398
Scott P KellyVaccines RWE Epidemiology, Pfizer Inc., New York, NY, USA.
Qing LiuVaccines RWE Epidemiology, Pfizer Inc., New York, NY, USA.
Jason D MaynardStrategic Analytics, Value and Economics, ADVI Health, Washington, DC, USA.
Heidi De SouzaStrategic Analytics, Value and Economics, ADVI Health, Washington, DC, USA.ORCID 0000-0002-7015-174X
Bradford D GessnerVaccines RWE Epidemiology, Pfizer Inc., New York, NY, USA.ORCID 0000-0002-6216-7194
Elizabeth BegierGlobal Medical Strategy, RSV Adult Vaccine Program, Pfizer Healthcare Ireland, Dublin, Ireland.ORCID 0000-0002-1287-5416

Funding

Pfizer
6 · The paper itself

Abstract

backgroundGuillain-Barré syndrome (GBS) is considered a rare complication of viral respiratory infections (eg, influenza, severe acute respiratory syndrome coronavirus 2); however, its association with respiratory syncytial virus (RSV) infection has not been studied. We performed a self-controlled case series analysis to estimate GBS risk following medically attended RSV disease among older adults.

methodsWe identified adults aged ≥65 years with medically attended RSV disease and incident inpatient GBS using specific International Classification of Diseases (ICD) codes, excluding those with prior GBS, from the US Medicare claims data (2011-2024). Risk period was 1 to 42 days after the RSV disease index date; the control period encompassed -180 to -22 days and 43 to 180 days of RSV disease index date. Conditional Poisson regression estimated RSV-related GBS incidence rate ratios (IRRs), adjusting for seasonality and viral activities. Medicare data policies prohibit cell case counts <11 from being displayed.

resultsAmong 452 471 eligible patients with RSV disease, <11 incident GBS cases occurred in the risk period and 34 during the control period. The adjusted IRR for GBS after RSV disease was 2.11 (95% confidence interval, 1.01-4.37), consistent across sensitivity analyses of alternative risk/control periods and after excluding coinfections. The IRR increased to 2.59 (1.17-5.73) after ICD-10 code adoption, with a marked rise among patients aged ≥75 years (3.98 [1.45-10.91]).

conclusionsGBS risk increases after RSV disease compared to control periods not temporally adjacent to RSV disease, with an effect particularly evident among patients aged ≥75 years. RSV should be recognized as 1 of the pathogens that may rarely lead to GBS.

Indexed as

Guillain-Barre SyndromeRespiratory Syncytial Virus InfectionsAgedAged, 80 and overFemaleHumansIncidenceMaleMedicareRisk FactorsUnited StatesGuillain-Barré syndromeincidence rate ratiosolder adultsRSV

Identifiers

PMID41234154
PMCPMC13169517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.